Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD‐1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody‐dependent phagocytosis, a potential mechanism of resistance to anti–PD‐1 therapy. The pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Budha, Nageshwar, Wu, Chi‐Yuan, Tang, Zhiyu, Yu, Tian, Liu, Lucy, Xu, Fengyan, Gao, Yuying, Li, Ruiying, Zhang, Qiuyang, Wan, Ya, Sahasranaman, Srikumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835120/
https://www.ncbi.nlm.nih.gov/pubmed/36330700
http://dx.doi.org/10.1002/psp4.12880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835120/
https://www.ncbi.nlm.nih.gov/pubmed/36330700
http://dx.doi.org/10.1002/psp4.12880

Ejemplares similares